Companies / MDGL Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Ticker MDGL Exchange Nasdaq Sector Healthcare Industry Biotechnology Market cap $9.28B 52-week range $353.54 - $615.00 Valuation Share price $399.63 (close of Nov 6, 2026) P/E (TTM) -49.52x Price to book 14.80x Price to free cash flow -55.03x Enterprise value $9.12B Book value per share $27.00 Price performance Period Change 1 day -0.12% 5 days -7.14% 1 month -19.50% 3 months -21.70% 6 months -25.96% Year to date -31.38% 1 year -18.21% 3 years +171.17% 5 years +329.52% 10 years +2,479.92% All time +25.61%
Short interest As of Oct 15, 2026 Short % of float 11.10% Shares short 2.19M Days to cover 7.24 Change since prior report -8.42% Source FINRA consolidated short interest Profitability and growth Return on equity -47.83% Return on invested capital -31.58% Return on assets -22.89% Return on capital employed -31.61% Gross margin 94.14% Net margin -30.08% EBITDA margin -31.16% Cash flow and balance sheet Free cash flow yield (TTM) -1.82% Current ratio 3.05x Net debt to EBITDA 1.32x Latest reported year Period end Dec 31, 2025 Fiscal year 2025 Revenue $958.40M Cost of revenue $56.15M Gross profit $902.25M EBITDA -$298.59M Net income -$288.28M Earnings per share $-12.85 Research and development $388.52M Interest expense $22.31M Shares outstanding 22.43M Income statement by year Period end Revenue Gross profit Net income EPS 2025-12-31 $958.40M $902.25M -$288.28M -$12.85 2024-12-31 $180.13M $173.90M -$465.89M -$21.90 2023-12-31 - - -$373.63M -$19.99 2022-12-31 - - -$295.35M -$17.23 2021-12-31 - - -$241.85M -$14.63 2020-12-31 - - -$202.24M -$13.09 2019-12-31 - - -$83.95M -$5.45 2018-12-31 - - -$32.81M -$2.22 2017-12-31 - - -$31.15M -$2.54 2016-12-31 - - -$26.39M -$5.07
Margins and returns by year Period end Gross margin Net margin Return on equity Return on capital 2025-12-31 94.14% -30.08% -47.83% -31.58% 2024-12-31 96.54% -258.64% -61.76% -56.97% 2023-12-31 - - -92.18% -72.82% 2022-12-31 - - -149.63% -118.72% 2021-12-31 - - -123.32% -123.15% 2020-12-31 - - -84.28% -85.84% 2019-12-31 - - -20.15% -22.76% 2018-12-31 - - -6.88% -8.53% 2017-12-31 - - -17.09% -17.59% 2016-12-31 - - -72.47% -69.27%
Cash and debt by year Period end Cash Debt 2025-12-31 $198.69M $339.88M 2024-12-31 $931.25M $117.57M 2023-12-31 $634.13M $115.48M 2022-12-31 $358.77M $49.29M 2021-12-31 $36.27M - 2020-12-31 $54.00M - 2019-12-31 $46.70M - 2018-12-31 $57.38M - 2017-12-31 $191.53M - 2016-12-31 $40.50M -
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$190.02M $98.13M 2024-12-31 -$457.03M $79.88M 2023-12-31 -$325.71M $49.73M 2022-12-31 -$225.07M $31.63M 2021-12-31 -$184.13M $26.87M 2020-12-31 -$157.90M $20.73M 2019-12-31 -$41.80M $22.76M 2018-12-31 -$25.53M $13.49M 2017-12-31 -$22.44M $3.25M 2016-12-31 -$17.61M $7.93M
Investor relations Past earnings dates Reported Fiscal period EPS estimate 2026-11-03 Sep 2026 -$1.09 2026-07-30 Jun 2026 -$2.55 2026-05-06 Mar 2026 -$3.61 2026-02-19 Dec 2025 $0.03 2025-11-04 Sep 2025 -$1.98 2025-08-05 Jun 2025 -$3.48 2025-05-01 Mar 2025 -$3.62 2025-02-26 Dec 2024 -$4.12
Filings and sources Company website madrigalpharma.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades